培米替尼pemigatinib是治疗胆管癌的靶向药

Cholangiocarcinoma is a highly malignant tumor with strong invasiveness and poor prognosis. Many patients have lost the chance of surgery when diagnosed. Systemic treatment options for advanced cholangiocarcinoma are extremely scarce. The objective response rate of first-line standard chemotherapy is only 15%-26%. Drug resistance often occurs, and there is no standard second-line treatment plan. There is an urgent need for new treatment plans to improve patient survival. Pemigatinib is a targeted drug for the treatment of cholangiocarcinoma. It has been approved by the US FDA for marketing. It is mainly used to treat patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement. As the first targeted drug for cholangiocarcinoma, it is expected to change the clinical treatment landscape for patients with cholangiocarcinoma.

The phase 2 FIGHT-202 trial (NCT02924376) demonstrated the efficacy of pemigatinib in patients with locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements. In the trial, researchers reported an objective response rate (ORR) of 35.5%, a median progression-free response of 6.9 months, a median duration of response (DOR) of 9.1 months, and a disease control rate (DCR) of 82%.

Combining the trial data, it can be seen that pemigatinib can prolong the survival period of patients with cholangiocarcinoma, improve the remission rate, reduce the patient's pain, improve the patient's quality of life and disease progression, and has a significant therapeutic effect. The launch of pemigatinib brings more treatment options and options to patients with cholangiocarcinoma.

The above is the introduction about pemigatinib. If patients want to know more about the latest drug information about pemigatinib (such as price, purchase method, precautions, etc.), they can contact the Medical Companion Travel Service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: